{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:32:27Z","timestamp":1789561947010,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672696"],"award-info":[{"award-number":["81672696"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z161100000516062"],"award-info":[{"award-number":["Z161100000516062"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejca.2021.07.018","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T05:03:56Z","timestamp":1629435836000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma"],"prefix":"10.1016","volume":"156","author":[{"given":"Bixia","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-8621","authenticated-orcid":false,"given":"Jiazhi","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2021.07.018_bib1","first-page":"e23","article-title":"Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease","volume":"31","author":"Lerner","year":"2017","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"10.1016\/j.ejca.2021.07.018_bib2","doi-asserted-by":"crossref","first-page":"MMT11","DOI":"10.2217\/mmt-2018-0003","article-title":"Combatting mucosal melanoma: recent advances and future perspectives","volume":"5","author":"Tyrrell","year":"2018","journal-title":"Melanoma Manag"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.018_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/jop.12358","article-title":"Mutation scanning of BRAF, NRAS, KIT, and GNAQ\/GNA11 in oral mucosal melanoma: a study of 57 cases","volume":"45","author":"Lyu","year":"2016","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.018_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","article-title":"Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort","volume":"48","author":"Si","year":"2012","journal-title":"Eur J Canc"},{"issue":"6","key":"10.1016\/j.ejca.2021.07.018_bib5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2021.07.018_bib6","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, Efficacy and Biomarker Analysis of Toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Canc Res"},{"issue":"21","key":"10.1016\/j.ejca.2021.07.018_bib7","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.ejca.2021.07.018_bib8","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial","volume":"37","author":"Sheng","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.07.018_bib9","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced Solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl_4","key":"10.1016\/j.ejca.2021.07.018_bib10","first-page":"S1142","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004","volume":"31","author":"Arance Fernandez","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.018_bib11","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1200\/JCO.1997.15.7.2589","article-title":"Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy","volume":"15","author":"Leyvraz","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.07.018_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.cmr.0000129377.22141.ea","article-title":"Phase I\/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver","volume":"14","author":"Agarwala","year":"2004","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.018_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.ejca.2021.07.018_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2020.04.009","article-title":"Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: do they have a role in non-oncogene-addicted non-small cell lung cancer?","volume":"144","author":"Popat","year":"2020","journal-title":"Lung Canc"},{"issue":"6","key":"10.1016\/j.ejca.2021.07.018_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.07.018_bib16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.018_bib17","first-page":"5","article-title":"Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data","volume":"202","author":"Ott","year":"2015","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.018_bib18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.07.018_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CJI.0000000000000334","article-title":"Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study","volume":"43","author":"van Zeijl","year":"2020","journal-title":"J Immunother"},{"issue":"12","key":"10.1016\/j.ejca.2021.07.018_bib20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.018_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study","volume":"105","author":"Namikawa","year":"2018","journal-title":"Eur J Canc"},{"issue":"11","key":"10.1016\/j.ejca.2021.07.018_bib22","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/1346-8138.15521","article-title":"Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma","volume":"47","author":"Takahashi","year":"2020","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2021.07.018_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.07.018_bib24","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1245\/s10434-018-6465-y","article-title":"Patterns of treatment failure in patients with sinonasal mucosal melanoma","volume":"25","author":"Amit","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.018_bib25","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw694","article-title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","volume":"28","author":"Lian","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.07.018_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Canc Immunol Res"},{"issue":"3","key":"10.1016\/j.ejca.2021.07.018_bib27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.018_bib28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2021.07.018_bib29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fonc.2019.01157","article-title":"Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy","volume":"9","author":"Chiang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.07.018_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejca.2020.09.029","article-title":"Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus","volume":"142","author":"Dall'Armellina","year":"2021","journal-title":"Eur J Canc"},{"issue":"34","key":"10.1016\/j.ejca.2021.07.018_bib31","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.2217\/fon-2019-0465","article-title":"Survival outcomes of mucosal melanoma in the USA","volume":"15","author":"Al-Haseni","year":"2019","journal-title":"Future Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:45Z","timestamp":1760733165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":31,"alternative-id":["S0959804921004743"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}